Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial

Authors

  • Ellen Backlund Department of Oncology, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
  • Muyi Yang Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
  • Vitali Grozman Department of Diagnostic Radiology, Karolinska University Hospital, Sweden; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
  • Giuseppe Masucci Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
  • Johan Falkenius Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
  • Hanna Eriksson Department of Oncology, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
  • Braslav Jovanovic Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
  • Katarina Hammarlund Department of Oncology, Karolinska University Hospital, Stockholm, Sweden
  • Ulf Isacsson Medical Radiation Physics, Uppsala University Hospital, Uppsala, Sweden; Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
  • Calin Radu Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
  • Edvard Abel Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden
  • Kristin Karlsson Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden
  • Ricardo Palanco Zamora Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden
  • Peter Wersäll Department of Oncology, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
  • Ulrika Edbäck Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
  • Stina Wickström Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
  • Eva Darai Ramqvist Department of Clinical Pathology and Cytology, Karolinska University Hospital, Stockholm, Sweden
  • Suzanne Egyhazi Brage Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
  • Rolf Kiessling Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
  • Kristina Viktorsson Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
  • Bo Franzén Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
  • Rolf Lewensohn Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
  • Roger Olofsson Bagge Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
  • Gustav J. Ullenhag Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; Department of Oncology, Uppsala University Hospital, Uppsala, Sweden
  • Lars Ny Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden
  • Karin Lindberg Department of Oncology, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
  • Hildur Helgadottir Department of Oncology, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden

DOI:

https://doi.org/10.1080/0284186X.2022.2079959

Abstract

No abstracts available

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2022-07-03

How to Cite

Backlund, E., Yang, M., Grozman, V., Masucci, G., Falkenius, J., Eriksson, H., … Helgadottir, H. (2022). Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial. Acta Oncologica, 61(7), 869–873. https://doi.org/10.1080/0284186X.2022.2079959

Issue

Vol. 61 No. 7 (2022): Acta Oncologica

Section

Articles